TITLE

Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib

AUTHOR(S)
Nagai, Hidenari; Kanekawa, Takenori; Kobayashi, Kojiro; Mukozu, Takanori; Matsui, Daigo; Matsui, Teppei; Kanayama, Masahiro; Wakui, Noritaka; Momiyama, Kouichi; Shinohara, Mie; Ishii, Koji; Igarashi, Yoshinori; Sumino, Yasukiyo
PUB. DATE
February 2014
SOURCE
Cancer Chemotherapy & Pharmacology;Feb2014, Vol. 73 Issue 2, p223
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose: Recently, the oral multikinase inhibitor sorafenib has been used to treat advanced hepatocellular carcinoma (aHCC). Tumor necrosis factor (TNF) induces apoptosis of tumor cells by binding to TNF-related apoptosis-inducing ligand, while binding of the Fas ligand on cytotoxic T lymphocytes to the Fas receptor on hepatocytes also causes apoptosis. The aim of this study was to retrospectively evaluate changes of cytokines in patients with liver cirrhosis (LC) and aHCC receiving sorafenib therapy. Methods: Fifty-seven adult Japanese LC patients received sorafenib for aHCC (200-800 mg/day for 4 weeks) between 2009 and 2012 at our hospital. Blood samples were collected in the early morning before and after treatment, and the serum levels of soluble TNF-alpha (sTNF-alpha), soluble TNF receptor (sTNF-R), soluble Fas ligand (sFas L), and soluble Fas (sFas) were evaluated. Results: Ten patients were treated with sorafenib at 200 mg/day (200 mg group), 37 patients were given 400 mg/day (400 mg group), and 10 patients received 800 mg/day (800 mg group). The serum level of sTNF-alpha was significantly increased after treatment compared with before treatment in the 400 and 800 mg groups. The serum level of sTNF-R also showed a significant increase after treatment in the 400 mg group, although there was no significant difference of sTNF-R between before and after treatment in the 200 and 800 mg groups. sFas showed a significant decrease after treatment compared with before treatment in the 400 and 800 mg groups, although the serum level of sFas L never exceeded 0.15 ng/ml. Conclusions: These findings suggest that treatment with sorafenib at doses ≥400 mg/day might promote TNF-related or Fas-related apoptosis by increasing the circulating level of TNF-alpha or decreasing that of sFas.
ACCESSION #
94232537

 

Related Articles

  • Lymphotoxin Signaling Is Initiated by the Viral Polymerase in HCV-linked Tumorigenesis. Simonin, Yannick; Vegna, Serena; Akkari, Leila; Grégoire, Damien; Antoine, Etienne; Piette, Jacques; Floc'h, Nicolas; Lassus, Patrice; Guann-Yi Yu; Rosenberg, Arielle R.; Karin, Michael; Durantel, David; Hibner, Urszula // PLoS Pathogens;Mar2013, Vol. 9 Issue 3, p1 

    Exposure to hepatitis C virus (HCV) typically results in chronic infection that leads to progressive liver disease ranging from mild inflammation to severe fibrosis and cirrhosis as well as primary liver cancer. HCV triggers innate immune signaling within the infected hepatocyte, a first step in...

  • Changes of cytokines in cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy. Nagai, Hidenari; Miyaki, Daisuke; Matsui, Teppei; Kanayama, Masahiro; Higami, Katsuya; Momiyama, Kouichi; Ikehara, Takashi; Watanabe, Manabu; Sumino, Yasukiyo; Miki, Kazumasa // Cancer Chemotherapy & Pharmacology;Jul2008, Vol. 62 Issue 2, p271 

    Tumor necrosis factor (TNF) induces cancer cell-specific apoptosis by binding to a TNF-related apoptosis-inducing ligand. Binding of the Fas ligand on cytotoxic T lymphocytes to the Fas receptor on hepatocytes is also known to induce apoptosis. The aim of this study was to clarify changes of...

  • JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand. S R Mucha // Gut;May2009, Vol. 58 Issue 5, p688 

    BACKGROUND: cJun terminal kinase (JNK) is constitutively activated in most hepatocellular carcinomas (HCCs), yet its exact role in carcinogenesis remains controversial. While tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is known as a major mediator of acquired immune...

  • Death receptor-independent FADD signalling triggers hepatitis and hepatocellular carcinoma in mice with liver parenchymal cell-specific NEMO knockout. Ehlken, H; Krishna-Subramanian, S; Ochoa-Callejero, L; Kondylis, V; Nadi, N E; Straub, B K; Schirmacher, P; Walczak, H; Kollias, G; Pasparakis, M // Cell Death & Differentiation;Nov2014, Vol. 21 Issue 11, p1721 

    Hepatocellular carcinoma (HCC) usually develops in the context of chronic hepatitis triggered by viruses or toxic substances causing hepatocyte death, inflammation and compensatory proliferation of liver cells. Death receptors of the TNFR superfamily regulate cell death and inflammation and are...

  • Effects of Pro-Inflammatory Cytokines on the Production of Soluble Fractalkine and ADAM17 by HepG2 Cells. Turner, Sharon L.; Mangnall, David; Bird, Nigel C.; Blair-Zajdel, Maria E.; Bunning, Rowena A. D. // Journal of Gastrointestinal & Liver Diseases;Sep2010, Vol. 19 Issue 3, p265 

    Background & Aims: Soluble fractalkine is increased in the liver during times of injury; however the effect of pro-inflammatory cytokines in this process is currently unknown. The aim of this study was to determine whether pro-inflammatory cytokines elevated in patients with hepatocellular...

  • Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy. Chacon, Jessica Ann; Pilon-thomas, Shari; Sarnaik, Amod A.; Radvanyi, Laszlo G. // OncoImmunology;Sep2013, Vol. 2 Issue 9, pe25581-1 

    Co-stimulation through members of the tumor necrosis factor receptor (TNFR) family appears to be critical for the generation of T cells with optimal effector-memory properties for adoptive cell therapy. Our work suggests that continuous 4-1BB/CD137 co-stimulation is required for the expansion of...

  • Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Jo, Minji; Kim, Tae-Hyoung; Seol, Dai-Wu; Esplen, James E.; Dorko, Kenneth; Billiar, Timothy R.; Strom, Stephen C. // Nature Medicine;May2000, Vol. 6 Issue 5, p564 

    Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been reported to induce apoptosis in various tumor cells but not in nontransformed, normal cells. Preclinical studies in mice and nonhuman primates have shown that administration of TRAIL can induce apoptosis in human tumors,...

  • How are hepatocytes sensitized to apoptosis? Nagaki, Masahito; Moriwaki, Hisataka // Journal of Gastroenterology;2002, Vol. 37 Issue 12, p1094 

    Editorial. Discusses how hepatocytes are sensitized to apoptosis. Three structurally related cell-surface receptors implicated in the transduction of apoptotic cell death signals; Effect of administration of tumor necrosis factor (TNF) on mice; Comparison of apoptosis mediated with TNF...

  • Increased tumour necrosis factor α production in mesenteric lymph nodes of cirrhotic patients with ascites. Genescà, J.; Martí, R.; Rojo, F.; Campos, F.; Peribáñez, V.; Gónzalez, A.; Castells, L.; Ruiz-Marcellán, C.; Margarit, C.; Esteban, R.; Guardia, J.; Segura, R. // Gut;Jul2003, Vol. 52 Issue 7, p1054 

    Background: Cytokines produced in mesenteric lymph nodes of cirrhotic rats with bacterial translocation may participate in circulatory alterations of cirrhosis. Aim: To investigate whether cirrhotic patients present an increased local generation of cytokines in mesenteric lymph nodes. Methods:...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics